Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Medical ImagingNuclear Medical

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1394166

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1394166

Nuclear Medicine Market - Global Nuclear Medicine Market Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030 -

PUBLISHED:
PAGES: 206 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PPT Slides/PDF & Excel (Enterprise License)
USD 4995

Add to Cart

Description

Table of Contents

The global nuclear medicine market is poised for substantial growth, with a projected Compound Annual Growth Rate (CAGR) of 11.5% between 2023 and 2030, according to a recent market research report by Fairfield Market Research. The market, valued at approximately $5.2 billion in 2022, is expected to reach a significant valuation of $11.14 billion by the end of 2030. Several factors, including the increasing incidence of cardiac and cancer disorders and innovative approaches to address supply-demand imbalances in the nuclear medicine field, are contributing to this growth.

Growing Prevalence of Target Conditions

One of the key drivers fueling the expansion of the nuclear medicine market is the rising incidence and prevalence of cardiovascular diseases (CVD) and cancer worldwide. Early detection and treatment are crucial in managing these diseases, and nuclear medicine plays a vital role in this process.

For instance, CVD remains a leading cause of death globally, with millions of deaths attributed to it each year. Nuclear medicine techniques are essential for diagnosing and treating heart diseases, driving the demand for nuclear medicine procedures.

Expanding Applications for Early Disease Detection

Nuclear imaging techniques are used in a wide range of medical applications, including the early detection of central nervous system problems, intracranial tumors, arteriovenous malformations, heart diseases, and breast diseases. These techniques offer precise molecular activity detection, enabling early disease identification and treatment evaluation.

The expanding use of nuclear medicine for early disease detection is expected to drive the global nuclear medicine market's growth during the forecast period.

Increasing Incidence of Chronic Diseases

The global burden of chronic diseases such as cardiovascular diseases, cancer, respiratory problems, neurological disorders, and metabolic disorders is on the rise. Early detection and treatment are crucial in managing these conditions, and nuclear medicine is highly sought after for its diagnostic and therapeutic applications.

The market is further fueled by the growing adoption of nuclear medicine procedures for detecting and treating various diseases, including lymphoma, heart diseases, and more.

Challenges in the Market

Despite its promising growth, the nuclear medicine market faces challenges, including the high costs associated with hybrid imaging devices and the short shelf life of radiopharmaceuticals. High price points of hybrid imaging devices often lead to a preference for less expensive conventional imaging systems, while the short shelf life of radiopharmaceuticals can lead to their deterioration before use, raising concerns about safety and efficacy.

Regulatory Impact

Strict regulatory guidelines are in place to ensure the quality, safety, and potency of radiopharmaceuticals used in nuclear medicine procedures. Regulatory bodies in various countries oversee the production, administration, storage, and disposal of radionuclides, with guidelines designed to enhance radiation safety for patients and healthcare workers.

The regulatory landscape varies by region, with agencies like the US FDA, European regulatory authorities, and India's Atomic Energy Regulatory Board (AERB) setting standards for the safe use of nuclear medicine in healthcare.

Regional Insights

  • North America: North America is a major market player, with a significant portion of the population suffering from cancer and cardiovascular disorders. The region's market growth is driven by factors such as accessible radiopharmaceuticals, physician adoption of nuclear medicine, and technological advancements.
  • Asia Pacific: The Asia Pacific region is experiencing substantial growth in the nuclear medicine market due to rising awareness, increasing rates of chronic diseases, growing healthcare expenditures, and expanding applications of SPECT and PET. Countries like China, India, and Japan are contributing significantly to market expansion.

Leaders in the Global Nuclear Medicine Market

The global nuclear medicine market is characterized by consolidation, with a few major players dominating the industry. Leading companies in the nuclear medicine space include:

  • 1. Advanced Accelerator Applications
  • 2. Norgine B.V.
  • 3. Blue Earth Diagnostics Ltd.
  • 4. Curium Pharma
  • 5. Digirad Corporation
  • 6. Jubilant Radiopharma
  • 7. Karyopharm
  • 8. Lantheus Holdings, Inc.
  • 9. Northstar Nuclear Medicine
  • 10. Precirix NV
  • 11. Sinotau Pharmaceuticals
  • 12. Solcom
  • 13. Zionexa
  • 14. Cardinal Health
  • 15. Bracco Diagnostic Inc.

Global Nuclear Medicine Market is Categorised as Below:

By Product Type:

  • Diagnostics
    • Single Photon Emission Computed Tomography (SPECT)
    • Positron Emission Tomography (PET)
  • Therapeutics
    • Alpha Emitters
    • Beta Emitters
    • Brachytherapy

By Application:

  • Cardiology
  • Neurology
  • Oncology
  • Thyroid
  • Lymphoma
  • Other Application

By End User:

  • Hospitals & Clinics
  • Diagnostic Centres
  • Others

By Geographic Coverage:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Turkey
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Egypt
    • Nigeria
    • Rest of Middle East & Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Nuclear Medicine Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2022
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Nuclear Medicine Market Outlook, 2018 - 2030

  • 3.1. Global Nuclear Medicine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2030
    • 3.1.1. Key Highlights
      • 3.1.1.1. Diagnostics
        • 3.1.1.1.1. Single Photon Emission Computed Tomography (SPECT)
        • 3.1.1.1.2. Positron Emission Tomography (PET)
      • 3.1.1.2. Therapeutics
        • 3.1.1.2.1. Alpha Emitters
        • 3.1.1.2.2. Beta Emitters
        • 3.1.1.2.3. Brachytherapy
  • 3.2. Global Nuclear Medicine Market Outlook, by Application, Value (US$ Bn), 2018 - 2030
    • 3.2.1. Key Highlights
      • 3.2.1.1. Cardiology
      • 3.2.1.2. Neurology
      • 3.2.1.3. Oncology
      • 3.2.1.4. Thyroid
      • 3.2.1.5. Lymphoma
      • 3.2.1.6. Other Application
  • 3.3. Global Nuclear Medicine Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
    • 3.3.1. Key Highlights
      • 3.3.1.1. Hospitals & Clinics
      • 3.3.1.2. Diagnostic Centres
      • 3.3.1.3. Others
  • 3.4. Global Nuclear Medicine Market Outlook, by Region, Value (US$ Bn), 2018 - 2030
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Nuclear Medicine Market Outlook, 2018 - 2030

  • 4.1. North America Nuclear Medicine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2030
    • 4.1.1. Key Highlights
      • 4.1.1.1. Diagnostics
        • 4.1.1.1.1. Single Photon Emission Computed Tomography (SPECT)
        • 4.1.1.1.2. Positron Emission Tomography (PET)
      • 4.1.1.2. Therapeutics
        • 4.1.1.2.1. Alpha Emitters
        • 4.1.1.2.2. Beta Emitters
        • 4.1.1.2.3. Brachytherapy
  • 4.2. North America Nuclear Medicine Market Outlook, by Application, Value (US$ Bn), 2018 - 2030
    • 4.2.1. Key Highlights
      • 4.2.1.1. Cardiology
      • 4.2.1.2. Neurology
      • 4.2.1.3. Oncology
      • 4.2.1.4. Thyroid
      • 4.2.1.5. Lymphoma
      • 4.2.1.6. Other Application
  • 4.3. North America Nuclear Medicine Market Outlook, by End User Assessment, Value (US$ Bn), 2018 - 2030
    • 4.3.1. Key Highlights
      • 4.3.1.1. Key Highlights
      • 4.3.1.2. Hospitals & Clinics
      • 4.3.1.3. Diagnostic Centres
      • 4.3.1.4. Others
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis
  • 4.4. North America Nuclear Medicine Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
      • 4.4.1.2. U.S. Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
      • 4.4.1.3. U.S. Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
      • 4.4.1.4. Canada Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
      • 4.4.1.5. Canada Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
      • 4.4.1.6. Canada Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Nuclear Medicine Market Outlook, 2018 - 2030

  • 5.1. Europe Nuclear Medicine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2030
    • 5.1.1. Key Highlights
      • 5.1.1.1. Diagnostics
        • 5.1.1.1.1. Single Photon Emission Computed Tomography (SPECT)
        • 5.1.1.1.2. Positron Emission Tomography (PET)
      • 5.1.1.2. Therapeutics
        • 5.1.1.2.1. Alpha Emitters
        • 5.1.1.2.2. Beta Emitters
        • 5.1.1.2.3. Brachytherapy
  • 5.2. Europe Nuclear Medicine Market Outlook, by Application, Value (US$ Bn), 2018 - 2030
    • 5.2.1. Key Highlights
      • 5.2.1.1. Cardiology
      • 5.2.1.2. Neurology
      • 5.2.1.3. Oncology
      • 5.2.1.4. Thyroid
      • 5.2.1.5. Lymphoma
      • 5.2.1.6. Other Application
  • 5.3. Europe Nuclear Medicine Market Outlook, by End User Assessment, Value (US$ Bn), 2018 - 2030
    • 5.3.1. Key Highlights
      • 5.3.1.1. Hospitals & Clinics
      • 5.3.1.2. Diagnostic Centres
      • 5.3.1.3. Others
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis
  • 5.4. Europe Nuclear Medicine Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
      • 5.4.1.2. Germany Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
      • 5.4.1.3. Germany Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
      • 5.4.1.4. U.K. Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
      • 5.4.1.5. U.K. Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
      • 5.4.1.6. U.K. Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
      • 5.4.1.7. France Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
      • 5.4.1.8. France Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
      • 5.4.1.9. France Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
      • 5.4.1.10. Italy Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
      • 5.4.1.11. Italy Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
      • 5.4.1.12. Italy Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
      • 5.4.1.13. Turkey Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
      • 5.4.1.14. Turkey Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
      • 5.4.1.15. Turkey Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
      • 5.4.1.16. Russia Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
      • 5.4.1.17. Russia Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
      • 5.4.1.18. Russia Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
      • 5.4.1.19. Rest of Europe Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
      • 5.4.1.20. Rest of Europe Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
      • 5.4.1.21. Rest of Europe Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Nuclear Medicine Market Outlook, 2018 - 2030

  • 6.1. Asia Pacific Nuclear Medicine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2030
    • 6.1.1. Key Highlights
      • 6.1.1.1. Diagnostics
        • 6.1.1.1.1. Single Photon Emission Computed Tomography (SPECT)
        • 6.1.1.1.2. Positron Emission Tomography (PET)
      • 6.1.1.2. Therapeutics
        • 6.1.1.2.1. Alpha Emitters
        • 6.1.1.2.2. Beta Emitters
        • 6.1.1.2.3. Brachytherapy
  • 6.2. Asia Pacific Nuclear Medicine Market Outlook, by Application, Value (US$ Bn), 2018 - 2030
    • 6.2.1. Key Highlights
      • 6.2.1.1. Cardiology
      • 6.2.1.2. Neurology
      • 6.2.1.3. Oncology
      • 6.2.1.4. Thyroid
      • 6.2.1.5. Lymphoma
      • 6.2.1.6. Other Application
  • 6.3. Asia Pacific Nuclear Medicine Market Outlook, by End User Assessment, Value (US$ Bn), 2018 - 2030
    • 6.3.1. Key Highlights
      • 6.3.1.1. Hospitals & Clinics
      • 6.3.1.2. Diagnostic Centres
      • 6.3.1.3. Others
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis
  • 6.4. Asia Pacific Nuclear Medicine Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
      • 6.4.1.2. China Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
      • 6.4.1.3. China Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
      • 6.4.1.4. Japan Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
      • 6.4.1.5. Japan Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
      • 6.4.1.6. Japan Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
      • 6.4.1.7. South Korea Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
      • 6.4.1.8. South Korea Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
      • 6.4.1.9. South Korea Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
      • 6.4.1.10. India Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
      • 6.4.1.11. India Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
      • 6.4.1.12. India Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
      • 6.4.1.13. Southeast Asia Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
      • 6.4.1.14. Southeast Asia Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
      • 6.4.1.15. Southeast Asia Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
      • 6.4.1.16. Rest of Asia Pacific Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
      • 6.4.1.17. Rest of Asia Pacific Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
      • 6.4.1.18. Rest of Asia Pacific Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Nuclear Medicine Market Outlook, 2018 - 2030

  • 7.1. Latin America Nuclear Medicine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2030
    • 7.1.1. Key Highlights
      • 7.1.1.1. Diagnostics
        • 7.1.1.1.1. Single Photon Emission Computed Tomography (SPECT)
        • 7.1.1.1.2. Positron Emission Tomography (PET)
      • 7.1.1.2. Therapeutics
        • 7.1.1.2.1. Alpha Emitters
        • 7.1.1.2.2. Beta Emitters
        • 7.1.1.2.3. Brachytherapy
  • 7.2. Latin America Nuclear Medicine Market Outlook, by Application, Value (US$ Bn), 2018 - 2030
    • 7.2.1. Key Highlights
      • 7.2.1.1. Cardiology
      • 7.2.1.2. Neurology
      • 7.2.1.3. Oncology
      • 7.2.1.4. Thyroid
      • 7.2.1.5. Lymphoma
      • 7.2.1.6. Other Application
  • 7.3. Latin America Nuclear Medicine Market Outlook, by End User Assessment, Value (US$ Bn), 2018 - 2030
    • 7.3.1. Key Highlights
      • 7.3.1.1. Hospitals & Clinics
      • 7.3.1.2. Diagnostic Centres
      • 7.3.1.3. Others
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis
  • 7.4. Latin America Nuclear Medicine Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
      • 7.4.1.2. Brazil Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
      • 7.4.1.3. Brazil Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
      • 7.4.1.4. Mexico Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
      • 7.4.1.5. Mexico Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
      • 7.4.1.6. Mexico Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
      • 7.4.1.7. Argentina Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
      • 7.4.1.8. Argentina Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
      • 7.4.1.9. Argentina Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
      • 7.4.1.10. Rest of Latin America Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
      • 7.4.1.11. Rest of Latin America Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
      • 7.4.1.12. Rest of Latin America Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Nuclear Medicine Market Outlook, 2018 - 2030

  • 8.1. Middle East & Africa Nuclear Medicine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2030
    • 8.1.1. Key Highlights
      • 8.1.1.1. Diagnostics
        • 8.1.1.1.1. Single Photon Emission Computed Tomography (SPECT)
        • 8.1.1.1.2. Positron Emission Tomography (PET)
      • 8.1.1.2. Therapeutics
        • 8.1.1.2.1. Alpha Emitters
        • 8.1.1.2.2. Beta Emitters
        • 8.1.1.2.3. Brachytherapy
  • 8.2. Middle East & Africa Nuclear Medicine Market Outlook, by Application, Value (US$ Bn), 2018 - 2030
    • 8.2.1. Key Highlights
      • 8.2.1.1. Cardiology
      • 8.2.1.2. Neurology
      • 8.2.1.3. Oncology
      • 8.2.1.4. Thyroid
      • 8.2.1.5. Lymphoma
      • 8.2.1.6. Other Application
  • 8.3. Middle East & Africa Nuclear Medicine Market Outlook, by End User Assessment, Value (US$ Bn), 2018 - 2030
    • 8.3.1. Key Highlights
      • 8.3.1.1. Hospitals & Clinics
      • 8.3.1.2. Diagnostic Centres
      • 8.3.1.3. Others
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis
  • 8.4. Middle East & Africa Nuclear Medicine Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
      • 8.4.1.2. GCC Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
      • 8.4.1.3. GCC Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
      • 8.4.1.4. South Africa Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
      • 8.4.1.5. South Africa Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
      • 8.4.1.6. South Africa Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
      • 8.4.1.7. Egypt Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
      • 8.4.1.8. Egypt Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
      • 8.4.1.9. Egypt Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
      • 8.4.1.10. Nigeria Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
      • 8.4.1.11. Nigeria Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
      • 8.4.1.12. Nigeria Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
      • 8.4.1.13. Rest of Middle East & Africa Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
      • 8.4.1.14. Rest of Middle East & Africa Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
      • 8.4.1.15. Rest of Middle East & Africa Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Manufacturer vs Product/Application Heatmap
  • 9.2. Company Market Share Analysis, 2022
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Advanced Accelerator Applications
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Norgine B.V.
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. Blue Earth Diagnostics Ltd.
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Curium Pharma
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Digirad Corporation
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Jubilant Radiopharma
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Karyopharm
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Lantheus Holdings, Inc.
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Northstar Nuclear Medicine
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Business Strategies and Development
    • 9.4.10. Precirix NV
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development
    • 9.4.11. Sinotau Pharmaceuticals
      • 9.4.11.1. Company Overview
      • 9.4.11.2. Product Portfolio
      • 9.4.11.3. Financial Overview
      • 9.4.11.4. Business Strategies and Development
    • 9.4.12. Solcom
      • 9.4.12.1. Company Overview
      • 9.4.12.2. Product Portfolio
      • 9.4.12.3. Financial Overview
      • 9.4.12.4. Business Strategies and Development
    • 9.4.13. Zionexa
      • 9.4.13.1. Company Overview
      • 9.4.13.2. Product Portfolio
      • 9.4.13.3. Financial Overview
      • 9.4.13.4. Business Strategies and Development
    • 9.4.14. Cardinal Health
      • 9.4.14.1. Company Overview
      • 9.4.14.2. Product Portfolio
      • 9.4.14.3. Financial Overview
      • 9.4.14.4. Business Strategies and Development
    • 9.4.15. Bracco Diagnostic Inc.
      • 9.4.15.1. Company Overview
      • 9.4.15.2. Product Portfolio
      • 9.4.15.3. Financial Overview
      • 9.4.15.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!